Browsing: Medication & Drugs

In a concerted effort to combat the pervasive issue of substance abuse, the Department of Health (DOH) recently initiated the Biyaheng Kalusugan: Drug Abuse Prevention and Control (DAPC) Week. This transformative event, held in collaboration with a variety of stakeholders, seeks to mobilise communities, fostering awareness about the danger of substance abuse and advocating for healthier choices, community resilience, and robust support systems.

With the emergence and increasing popularity of glucagon-like peptide 1 (GLP-1) agonists for the treatment of obesity in recent years, it might be worth investigating if these agents are able to reduce the cardiovascular risks associated with overweight and obesity, especially since they have been shown to reduce risk of major adverse cardiovascular events in patients with type 2 diabetes who are at high cardiovascular risk.

Log In or Register as a healthcare professional to read the full article.

Iron deficiency is present in 50% of the patients with heart failure and it is associated with worse symptoms and outcomes [1]. There have been a few studies analysing the benefit of intravenous (IV) ferric carboxymaltose in heart failure with iron deficiency. In the AFFIRM-AHF [2] trial, administration of IV ferric carboxymaltose reduced the risk of cardiovascular death and total hospitalisations for heart failure in patients hospitalized for acute heart failure.

Log In or Register as a healthcare professional to read the full article.

In a bold move, Thailand’s Prime Minister, Srettha Thavisin, announced a resolve to revise the country’s cannabis policy. Thavisin intends to move the country towards only allowing medical cannabis use within six months. This comes after a surge of nearly 6,000 cannabis dispensaries sprouted across the nation following its groundbreaking decriminalisation of cannabis a year ago, making it the first in Asia to do so.